Brooktree Capital Management Sells 9,877 Shares of Pfizer Inc. (NYSE:PFE)

Brooktree Capital Management lowered its position in Pfizer Inc. (NYSE:PFE) by 7.9% in the 4th quarter, Holdings Channel reports. The firm owned 115,135 shares of the biopharmaceutical company’s stock after selling 9,877 shares during the quarter. Pfizer accounts for approximately 2.7% of Brooktree Capital Management’s portfolio, making the stock its 15th biggest position. Brooktree Capital Management’s holdings in Pfizer were worth $3,315,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the third quarter valued at approximately $30,000. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $36,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Stock Up 3.2 %

NYSE PFE traded up $0.83 on Wednesday, hitting $26.45. The stock had a trading volume of 37,053,897 shares, compared to its average volume of 41,892,395. The business’s fifty day moving average price is $26.88 and its 200 day moving average price is $28.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The stock has a market cap of $149.77 billion, a price-to-earnings ratio of 73.89, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.14 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.35%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.